Chiasma Inc (CHMA)

3.76  -0.24 (-6%)

After market: 3.78 +0.02 (+0.53%)

News Image
3 years ago - Pulmatrix, Inc.

Pulmatrix appoints Director Anand Varadan

News Image
3 years ago - Chiasma

Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency

Submission supported by previously announced data from Phase 3 MPOWERED™ study

News Image
3 years ago - Chiasma

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--